These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 12201487

  • 1. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.
    Teicher BA, Menon K, Alvarez E, Shih C, Faul MM.
    Invest New Drugs; 2002 Aug; 20(3):241-51. PubMed ID: 12201487
    [Abstract] [Full Text] [Related]

  • 2. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.
    Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM.
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):473-80. PubMed ID: 11800028
    [Abstract] [Full Text] [Related]

  • 3. Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.
    Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM.
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):69-77. PubMed ID: 11855754
    [Abstract] [Full Text] [Related]

  • 4. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
    Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM.
    Anticancer Res; 2001 Jan; 21(5):3175-84. PubMed ID: 11848470
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
    Tyulyandina A, Harrison D, Yin W, Stepanova E, Kochenkov D, Solomko E, Peretolchina N, Daeyaert F, Joos JB, Van Aken K, Byakhov M, Gavrilova E, Tjulandin S, Tsimafeyeu I.
    Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
    [Abstract] [Full Text] [Related]

  • 8. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide.
    Takahashi N, Haba A, Matsuno F, Seon BK.
    Cancer Res; 2001 Nov 01; 61(21):7846-54. PubMed ID: 11691802
    [Abstract] [Full Text] [Related]

  • 9. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.
    Shalinsky DR, Brekken J, Zou H, Bloom LA, McDermott CD, Zook S, Varki NM, Appelt K.
    Clin Cancer Res; 1999 Jul 01; 5(7):1905-17. PubMed ID: 10430098
    [Abstract] [Full Text] [Related]

  • 10. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.
    Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA.
    Cancer Chemother Pharmacol; 2004 Feb 01; 53(2):133-40. PubMed ID: 14593497
    [Abstract] [Full Text] [Related]

  • 11. Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma models.
    Herbst RS, Takeuchi H, Teicher BA.
    Cancer Chemother Pharmacol; 1998 Feb 01; 41(6):497-504. PubMed ID: 9554595
    [Abstract] [Full Text] [Related]

  • 12. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
    Teicher BA, Chen V, Shih C, Menon K, Forler PA, Phares VG, Amsrud T.
    Clin Cancer Res; 2000 Mar 01; 6(3):1016-23. PubMed ID: 10741729
    [Abstract] [Full Text] [Related]

  • 13. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.
    Cancer Res; 2003 Sep 15; 63(18):5978-91. PubMed ID: 14522925
    [Abstract] [Full Text] [Related]

  • 14. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization.
    Schiller JH, Bittner G.
    Clin Cancer Res; 1999 Dec 15; 5(12):4287-94. PubMed ID: 10632372
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 16. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N, Ideyama Y, Yamano M, Kuromitsu S, Tajinda K, Samizu K, Hisamichi H, Matsuhisa A, Shirasuna K, Kudoh M, Shibasaki M.
    Clin Cancer Res; 2006 Mar 01; 12(5):1630-8. PubMed ID: 16533791
    [Abstract] [Full Text] [Related]

  • 17. MicroPET imaging of tumor angiogenesis and monitoring on antiangiogenic therapy with an (18)F labeled RGD-based probe in SKOV-3 xenograft-bearing mice.
    Yang G, Nie P, Kong Y, Sun H, Hou G, Han J.
    Tumour Biol; 2015 May 01; 36(5):3285-91. PubMed ID: 25501513
    [Abstract] [Full Text] [Related]

  • 18. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, Scanziani E, Eccles SA, Bani MR, Giavazzi R.
    Clin Cancer Res; 2006 Mar 15; 12(6):1839-49. PubMed ID: 16551869
    [Abstract] [Full Text] [Related]

  • 19. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
    Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI, Giavazzi R.
    Clin Cancer Res; 2003 Aug 15; 9(9):3476-85. PubMed ID: 12960140
    [Abstract] [Full Text] [Related]

  • 20. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A.
    Mol Cancer Ther; 2007 Jul 15; 6(7):2003-11. PubMed ID: 17620430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.